Stock vs Stock Comparison

Vertex Pharmaceuticals Incorporated vs Eli Lilly and Company

VRTX wins the Tale of the Tape 5–4.

VRTX$425.09
LLY$1064.15

🏆 Tale of the Tape

54
VRTXLLY
32.9%Profitability (Net Margin)31.7%
26.5xValuation (P/E)39.2x
16.9%Efficiency (ROIC)30.4%
6/9Health (Piotroski F)7/9
11.7Safety (Altman Z)7.8
8.9%Growth (Rev YoY)44.7%
-0.20Risk (Sharpe 1Y)0.61
0.37xBalance Sheet (D/E)3.24x
2.96%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.345
252-Day Correlation
0.407
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricVRTXLLY
Market Cap$113.6B$985.4B
P/E Ratio26.5x39.2x
Forward P/E20.8x24.8x
P/B5.87x31.65x
Dividend Yield0.63%
Beta0.300.48

Quantitative Metrics

MetricVRTXLLY
DCF Fair Value$194.71$296.11
DCF Upside-55.8%-68.2%
Piotroski F6/97/9
Altman Z11.697.84
Beneish M-2.20-1.91
FCF Yield2.96%0.68%
Net Debt/EBITDA-0.6x1.1x
ROIC16.9%30.4%
WACC7.9%7.8%
ROIC – WACC9.0pp22.5pp
Gross Margin86.2%83.0%
Net Margin32.9%31.7%
Rev Growth YoY8.9%44.7%
Sharpe (1Y)-0.200.61
Max Drawdown 3Y
FCF Payout Ratio90%

VRTX Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

VRTX found in:

IBB7.20%
XLV2.06%
VHT1.75%
XBI1.02%
QUS0.68%
QQQ0.63%
MGK0.54%
SCHG0.48%
IWF0.41%
SPYV0.38%
VONG0.35%
VUG0.33%
ESGV0.23%
RSP0.21%
SCHX0.20%
IVV0.20%
SCHB0.19%
SPLG0.18%
VOO0.18%
ITOT0.17%
SPY0.17%
SPTM0.16%
VONE0.16%
VTI0.16%
URTH0.15%
ACWI0.13%
VT0.10%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

VRTX vs LLY: Head-to-Head Analysis

Vertex Pharmaceuticals Incorporated (VRTX) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, VRTX leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, VRTX generates a return on invested capital (ROIC) of 16.9% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between VRTX and LLY is 0.345, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

VRTX appears in 27 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, VRTX or LLY?

Our quantitative analysis compares VRTX and LLY across nine fundamental dimensions. VRTX wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are VRTX and LLY correlated?

The 252-day correlation between VRTX and LLY is 0.345. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.